Clinical Trials

60 enrolled

Prostatic Neoplasms

NCT07103018 2026-03-16

STRIKE-001

144 enrolled

Urogenital Diseases, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

75 enrolled

Prostatic Neoplasms

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT06463457 2026-03-09

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

33 enrolled

Prostatic Neoplasms

NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Phase 1 Completed

10 enrolled

Prostatic Neoplasms

NCT07450599 2026-03-05

CHINANEO

250 enrolled

High-Risk Localized Prostate Cancer

NCT04736199 2026-02-27

ARANOTE

Phase 3 Completed

669 enrolled 16 charts

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT05617885 2026-02-27

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

9 enrolled

Prostatic Neoplasms

NCT05997615 2026-02-24

AMX-500

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

277 enrolled

Phase 4 Active not recruiting

Metastatic Castration-resistant Prostate Neoplasms

NCT06627530 2026-02-11

COAction

144 enrolled

Prostatic Neoplasms

NCT05059236 2026-02-09

ARASEC

223 enrolled

Prostatic Neoplasms

NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

30 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT07244341 2026-02-04

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

60 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05348876 2026-01-30

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Phase 4 Recruiting

50 enrolled

Prostatic Neoplasms

NCT06120491 2026-01-21

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT05519449 2026-01-20

ENGAGER-PSMA-01

272 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06592924 2026-01-14

TRIPLE-SWITCH

830 enrolled

Phase 4 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

80 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

234 enrolled

Prostatic Neoplasms

NCT07282197 2025-12-15

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

40 enrolled

Prostatic Neoplasms

NCT04335682 2025-11-04

ARACOG

111 enrolled

Prostatic Neoplasms

NCT02972060 2025-09-19

ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

61 enrolled

Prostatic Neoplasms

NCT07172685 2025-09-15

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Phase NA Recruiting

116 enrolled

Prostatic Neoplasms

NCT03385655 2025-08-21

Prostate Cancer Biomarker Enrichment and Treatment Selection

200 enrolled

Prostatic Neoplasms

NCT04319783 2025-08-21

DECREASE

65 enrolled

Prostatic Neoplasms

NCT06401980 2025-08-14

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

162 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

250 enrolled

Prostatic Neoplasms

NCT05171387 2025-06-22

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

Phase 2 Completed

78 enrolled

Prostatic Neoplasms

NCT07027124 2025-06-18

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

40 enrolled

Prostatic Neoplasms

NCT04925648 2025-05-15

PICASSO

22 enrolled

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06190899 2025-03-21

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

54 enrolled

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

NCT06276465 2024-12-20

PEACE8

336 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

500 enrolled

Genital Diseases, Male, Prostatic Diseases

NCT04070209 2024-12-04

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

66 enrolled

Prostatic Neoplasms

NCT04916613 2024-09-26

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

300 enrolled

Prostate Cancer Metastatic

NCT06575257 2024-08-28

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

80 enrolled

Prostatic Neoplasms

NCT05762536 2024-06-27

DAROTAXEL

245 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT02933801 2024-03-13

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Phase 2 Terminated

92 enrolled

Prostatic Neoplasms

NCT05116475 2024-03-12

ALADDIN

152 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04641078 2024-02-28

DART

Phase 2 Unknown

124 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06282588 2024-02-28

THUNDER

Phase 2/3 Recruiting

493 enrolled

Prostatic Neoplasms

NCT04176081 2024-01-24

SChLAP/IDC

208 enrolled

BreastGenitourinary

Carcinoma, Intraductal, Noninfiltrating, Prostatic Neoplasms

NCT04737109 2023-11-13

ADDItion

Phase 1/2 Terminated

6 enrolled 9 charts